URGENT PANDEMIC INFORMATION

In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List


Wet AMD and DME Drug Development 2022


Date
Apr 05, 2022 - 08:00 AM - Apr 07, 05:00 PM
Organizer
Hanson Wade
Venue
Embassy Suites by Hilton Boston at Logan Airport
Location
207, Porter St

Boston,
MA,
USA,
ZIP: 02128
Phone: +16174554188

Ticket Price: USD 2599.0 - USD 5097.0


The second edition of the industry-led Wet AMD and DME Drug Development Summit arrives in Boston to give you comprehensive insight into the current and emerging angiogenesis- inflammatory-directed and anti-fibrotic drug development programs for these three ophthalmic conditions – neovascular age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and diabetic macular edema (DME).

Join this dedicated industry forum to network online and learn from senior leaders of discovery, translational sciences, and clinical development from the likes of Roche, Genentech, Novartis, Apellis, Outlook Therapeutics and more, to address the specific challenges for the biopharmaceutical and biotechnology in its efforts to bring long-lasting treatments which reduce clinical burden and can be commercialized to become the new standard-of-care in this vast ophthalmology indication.

Navigate across 3 jam-packed days including two interactive workshops exploring the optimization of administration techniques and viral and non-viral vectors to deliver safe and durable anti-angiogenic therapies to the eye and developing preclinical and translational models to predict human disease and efficacy of a drug.

Earlybird and group booking discounts available, visit the website for more information.

URLs:
Tickets: https://go.evvnt.com/988131-2?pid=1052
Brochure: https://go.evvnt.com/988131-3?pid=1052

Prices:
Pharma and Biotech Pricing - Conference + 2 Workshops: USD 4297.0,
Pharma and Biotech Pricing - Conference + 1 Workshop: USD 3648.0,
Pharma and Biotech Pricing - Conference Only: USD 2999.0,
Academic Pricing - Conference + 2 Workshops: USD 3697.0,
Academic Pricing - Conference + 1 Workshop: USD 3148.0,
Academic Pricing - Conference Only: USD 2599.0,
Solution Provider Pricing - Conference + 2 Workshops: USD 5097.0,
Solution Provider Pricing - Conference + 1 Workshop: USD 4348.0,
Solution Provider Pricing - Conference Only: USD 3599.0


Speaker Details


Peter Kaiser, Professor of Opthalmology, Cleveland Clinic, Eliot Lazar, President, Medical Doctor, eLCON Medical, Stefan Scheidl, Franchise Head, Disease Area Ophthalmology, Global Medical Affairs, Roche, Parisa Zamiri, Chief Medical Officer, Graybug Vision, Carlos Quezada-Ruiz, Senior Medical Director Ophthalmology, Clinical Science, PDS Clinical Science Team Leader, Genentech, David Lally, Vitreoretinal Surgeon and Clinical Investigator, New England Retina Associates, Kerrie Brady, Chief Executive Officer, OcuTerra, Thomas Ciulla, Chief Medical and Development Officer, Clearside Bio, Lukas Scheibler, Chief Innovation Officer, Apellis, Mina Sooch, Chief Executive Officer, Ocuphire, David Tanzer, Chief Medical Officer, OcuTerra, Victor Chong, MD, Vice President , Global Head of Retina, Janssen R and D, Russ Trenary, President and Chief Executive Officer, Outlook Therapeutics, Amir Shojaei, Chief Scientific Officer, AsclepiX Therapeutics, Maria Gemenetzi, Global Drug Development, CD and A, Novartis Pharmaceuticals Ltd, Zhichao Wu, Principal Investigator, Centre for Eye Research Australia, Konstantinos Balaskas, Consultant Ophthalmologist and Medical Retina Specialist, Director, Moorfields Ophthalmic Reading Centre and Clinical AI Lab, Marion Munk, Chief Medical Officer, Isarna Therapeutics, Sungjin Lee, Principal Scientist, Surrozen, Daniel Chung, Chief Medical Officer,SparingVision, Stephen Poor, Director External Innovation and Translational Biomarkers, Novartis Institutes for Biomedical Research, Department of Ophthalmology, Eric Nelson, Senior Business Development Consultant US, HealthVest, LLC, Robert Dempsey, Chief Executive Officer, AsclepiX Therapeutics, Eric Ng, Assistant Professor of Ophthalmology, Harvard Medical School, Stephen Pakola, Chief Medical Officer, REGENXBIO

Event Categories
Keywords: pharmaceutical




Comments








Events Calendar

SunMonTueWedThuFriSat
27 28 29 30 31 1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Event Location

Newsletters

VIP Life Time Subscription to our Newsletters!
$399.99
$299.99